India’s MedTech sector is evolving rapidly from import dependence to innovation leadership. Backed by progressive national policies, rising global investments, and expanding domestic manufacturing capacity, 2025 marks a turning point in India’s journey toward becoming a global MedTech hub.
Once heavily reliant on imported high-end devices, India’s MedTech sector is now shifting toward self-reliance and innovation. This transformation is driven by forward-looking policy frameworks, targeted incentives, and growing public–private partnerships that are catalyzing indigenous R&D and local manufacturing.
The National Medical Devices Policy (2023) laid the foundation for a robust ecosystem that encourages R&D, strengthens quality systems, and streamlines regulations. Complementing this, the Production-Linked Incentive (PLI) Scheme for Medical Devices continues to support the manufacturing of high-value products such as diagnostic imaging systems and implants under its revised guidelines and approved applicant list (2023).
The Scheme for Strengthening the Medical Device Industry (SMDI) and the creation of Medical Device Parks across states have further improved access to shared testing and prototyping facilities. Together, these initiatives aim to reduce import dependence—commonly reported at around 70–75%—and position India as a competitive, innovation-driven manufacturing base.
Also Read
In 2025, both domestic and multinational players are deepening their footprint in India’s MedTech landscape. States such as Haryana, Andhra Pradesh, and Telangana have introduced dedicated MedTech policies offering capital subsidies, plug-and-play infrastructure, and fast-track clearances to attract investors.
The Andhra Pradesh MedTech Zone (AMTZ) continues to serve as a model ecosystem, hosting more than 100 companies with in-house design, prototyping, and testing facilities. Its Innovation Passport program supports startups through regulatory mentoring and commercialization pathways, accelerating indigenous innovation.
Siemens Healthineers (Germany): Expanded its Bengaluru facility (inaugurated MRI production line in 2023) and continues capacity and AI-integrated radiology system investments.
Medtronic (USA): Reported investing in its Hyderabad operations (making it one of its largest R&D hubs outside the U.S., per 2025 company statements).
Philips Healthcare (Netherlands): Operating a multi-modality manufacturing unit in Pune focused on diagnostic imaging and connected-care solutions.
The Indian MedTech market, currently valued around US $12 billion, is projected to reach US $50 billion by 2030 (CAGR 15–18%, according to 2024–25 trade analyses). Domestic production is scaling quickly in disposables, diagnostics, and mid-range devices, while efforts are underway to localize complex components such as imaging modules and implants.
Despite strong momentum, several gaps remain:
Component-level manufacturing continues to rely on imports for critical sensors and microelectronics.
India requires more accredited testing and certification laboratories to meet global standards.
Skilled workforce shortages persist in device design, regulatory affairs, and quality management.
Timely disbursement of PLI incentives and faster rollout of SMDI facilities will be key to sustaining investor confidence.
India’s transition from an import-dependent market to an innovation-driven MedTech hub is well underway. The next milestone lies in execution—translating policies into certified facilities, resilient supply chains, and export-ready innovations.